Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945583 | 0.84 | ACACB (0.35) | ACACBACACAPRMT5WDR77KAT2B | |
| SCHEMBL26325733 | 0.84 | ACACB (0.35) | ACACBACACAPRMT5WDR77KAT2B | |
| SCHEMBL14945449 | 0.83 | ACACB (0.38) | ACACBACACAKAT2BBAZ2B | |
| SCHEMBL14945457 | 0.83 | ACACB (0.38) | ACACBACACAKAT2BBAZ2B | |
| SCHEMBL14945398 | 0.82 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14945397 | 0.82 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29642175 | 0.82 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL21816549 | 0.82 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29700513 | 0.82 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14948730 | 0.81 | SYK (0.39) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| EP-3329919-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 1148/4885CCNA2 2393/4885CDK2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.